Skip to content

INOVIO PHARMACEUTICALS, INC.: 10-Q filed 2025-08-12

What INOVIO PHARMACEUTICALS, INC. reported in its quarterly report filed 2025-08-12 (fiscal Q2 2025): 39 published measures, 111 facts as tagged in accession 0001055726-25-000055.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-12
Fiscal period
fiscal Q2 2025
Accession
0001055726-25-000055 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All INOVIO PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-3068,240,504USD
At 2024-12-31113,197,206USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-3039,709,599USD
At 2024-12-3144,693,411USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-3028,530,905USD
At 2025-03-3151,250,724USD
At 2024-12-3168,503,795USD
At 2024-06-3096,739,207USD
At 2024-03-3194,441,963USD
At 2023-12-31117,349,129USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-06-3024,351,377USD
At 2024-12-3165,813,297USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-23,519,412USD91
2025-01-01 to 2025-06-30-43,214,109USD181
2025-01-01 to 2025-03-31-19,694,697USD90
2024-04-01 to 2024-06-30-32,237,098USD91
2024-01-01 to 2024-06-30-62,706,969USD182
2024-01-01 to 2024-03-31-30,469,871USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-47,685,386USD181
2024-01-01 to 2024-06-30-56,969,306USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-01-01 to 2025-06-3090,303USD181
2024-01-01 to 2024-06-30487,832USD182

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD91
2025-01-01 to 2025-06-3065,343USD181
2024-04-01 to 2024-06-30100,762USD91
2024-01-01 to 2024-06-30100,762USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-30993,153USD181
2024-01-01 to 2024-06-3021,669,496USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-06-305,230,313USD181
2024-01-01 to 2024-06-3055,348,949USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-1,773,433,371USD
At 2024-12-31-1,730,219,262USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-04-01 to 2025-06-3038,830,053shares91
2025-01-01 to 2025-06-3038,722,451shares181
2024-04-01 to 2024-06-3027,197,802shares91
2024-01-01 to 2024-06-3025,244,657shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-3038,830,053shares91
2025-01-01 to 2025-06-3038,722,451shares181
2024-04-01 to 2024-06-3027,197,802shares91
2024-01-01 to 2024-06-3025,244,657shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.61USD/shares91
2025-01-01 to 2025-06-30-1.12USD/shares181
2024-04-01 to 2024-06-30-1.19USD/shares91
2024-01-01 to 2024-06-30-2.48USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-0.61USD/shares91
2025-01-01 to 2025-06-30-1.12USD/shares181
2024-04-01 to 2024-06-30-1.19USD/shares91
2024-01-01 to 2024-06-30-2.48USD/shares182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-06-303,089,293USD
At 2024-12-313,659,818USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-06-302,234,141USD181
2024-01-01 to 2024-06-304,039,486USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-23,084,519USD91
2025-01-01 to 2025-06-30-48,135,048USD181
2024-04-01 to 2024-06-30-33,196,913USD91
2024-01-01 to 2024-06-30-64,681,882USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-3052,697,149USD
At 2024-12-3197,830,050USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-3031,707,610USD
At 2024-12-3135,325,584USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-06-30840,312USD
At 2024-12-311,199,056USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-04-01 to 2025-06-3023,084,519USD91
2025-01-01 to 2025-06-3048,200,391USD181
2024-04-01 to 2024-06-3033,297,675USD91
2024-01-01 to 2024-06-3064,782,644USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-3014,521,407USD91
2025-01-01 to 2025-06-3030,612,309USD181
2024-04-01 to 2024-06-3023,090,989USD91
2024-01-01 to 2024-06-3044,001,307USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-3036,718,527shares
At 2024-12-3136,099,991shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-06-3024,351,377USD
At 2024-12-3165,813,297USD
At 2024-06-3034,392,404USD
At 2023-12-3114,310,862USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-301,802,589,299USD
At 2024-12-311,799,362,625USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-06-30-661,742USD
At 2024-12-31-675,667USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-06-307,356,238USD
At 2024-12-318,113,840USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-06-3010,658,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-06-302,012,476USD
At 2024-12-311,979,654USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-06-304,307,377USD
At 2024-12-312,517,465USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-23,519,834USD91
2025-01-01 to 2025-06-30-43,200,184USD181
2024-04-01 to 2024-06-30-32,250,420USD91
2024-01-01 to 2024-06-30-62,733,904USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-308,563,112USD91
2025-01-01 to 2025-06-3017,588,082USD181
2024-04-01 to 2024-06-3010,206,686USD91
2024-01-01 to 2024-06-3020,781,337USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-01-01 to 2025-06-30727,518USD181
2024-01-01 to 2024-06-30916,019USD182

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD91
2025-01-01 to 2025-06-300USD181
2024-04-01 to 2024-06-300USD91
2024-01-01 to 2024-06-30177,833USD182

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-703,183USD91
2025-01-01 to 2025-06-30-703,665USD181
2024-04-01 to 2024-06-307,571USD91
2024-01-01 to 2024-06-30-674,647USD182

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-06-300USD181
2024-01-01 to 2024-06-30533,487USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-06-301,102,149USD181
2024-01-01 to 2024-06-3022,284,801USD182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-358,744USD181
2024-01-01 to 2024-06-30-631,563USD182

Inspect the source

Entity
INOVIO PHARMACEUTICALS, INC. / CIK 0001055726
Captured
2026-09-20T05:17:43.559Z
SEC response SHA-256
9bfa830827e08b2d190e6d0b4ce0274a3c0d8852b6e536b16b5cfeadcaa54cf9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001055726.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))